DexCom

Dexcom makes small wearable devices that track blood sugar levels in real time. These tools help people with diabetes manage their health without constant finger pricks. Doctors and patients use this data to make better treatment decisions every day.

What Dexcom Sells

• G7 and G7 15 Day: Integrated continuous glucose monitoring (CGM) systems that send sugar readings to mobile devices every five minutes.
• Stelo: An over-the-counter glucose biosensor launched in August 2024 for adults with Type 2 diabetes who do not use insulin.
• Dexcom ONE+: A simplified sensor system designed for international markets to replace traditional finger stick blood sugar testing.
• Dexcom Share: A remote monitoring system that lets patients send their sugar data to the phones of up to ten followers.
• Data Solutions: Software like Dexcom Clarity that helps users and healthcare providers analyze long-term glucose trends in the cloud.

Growth and Expansion

• Launched Stelo in August 2024 as the first glucose biosensor available in the United States without a prescription.
• Obtained FDA marketing authorization for the G7 15 Day system in April 2025 for adults with diabetes.
• Entered a collaboration and license agreement with Verily Life Sciences LLC to develop new glucose monitoring products.
• Began building a new manufacturing facility in Athenry, Ireland, to increase production capacity for global markets.

Why the Company Stands Out

The company differentiates itself by integrating its sensors with a wide ecosystem of insulin pumps, smart pens, and wearable watches. Its technology uses a proprietary membrane and enzyme process to measure extremely small electrical signals for high accuracy.

The Scorecard

• Revenue reached $1.3 billion in Q4 2025, up 13.1% from Q4 2024.
• Operating income rose to $323 million in Q4 2025, a 71% increase year-over-year.
• Net income climbed to $267.3 million in Q4 2025, up 76.2% from the previous year.
• Free cash flow grew to $192.1 million in Q4 2025, up 8.7% from $176.8 million in Q4 2024.

Bottom Line

Dexcom has transitioned from a niche medical tool maker to a major provider of wearable health technology for the global diabetes population. Its expansion into over-the-counter sensors and integrated insulin delivery systems marks its evolution into a broader metabolic health company.